Dr. Stefanie Fischer Kontakt - Titel Vorname Nachname Land Mobilnummer E-Mail - Research KSSG

Dr. Stefanie Fischer

Kontakt
Titel         Dr. med

Vorname       Stefanie

Nachname      Fischer

Land          Switzerland

Mobilnummer   0767839062

E-Mail        stefanie.fischer@kssg.ch

Forschungsprofil
Akademischer Status   Oberarzt/Oberärztin

Departement           I

Abteilung             Onkologie/Hämatologie

Position              Oberärztin Onkologie/Hämatologie

Forschungsgebiet      Urogenitale Tumoren, Phase I

Mitgliedschaften      ESMO, EAU, SGMO

                                                     2

Publikationen
             Titel

Wissensch-   Fankhauser C D, Oldenburg J, Albers P, Algaba F, Bokemeyer C,
aftlicher    Boormans J L, Fischer S, Fizazi K, Gremmels H, Mayor De Castro J,
Artikel/     Janisch F, Muilwijk T, Leão R, Nicol D, Nicolai N, Tandstad T, Pilar Laguna
Review       M. Recommendations to Balance Benefits and Risks Of
             Thromboprophylaxis and to Avoid Central Venous-access Devices During
             First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The
             European Association Of Urology Testicular Cancer Panel Position in 2021.
             Eur Urol 2021; 80:4-6.

             Achard V, Putora P M, Omlin A, Zilli T, Fischer S. Metastatic Prostate
             Cancer: Treatment Options. Oncology 2021; 100:48-59.

             Beyer J, Berthold D, Bode P K, Cathomas R, Fankhauser C D, Fischer S,
             Gillessen S, Gross T, Hermanns T, Honecker F, Lorch A, Omlin A,
             Papachristofilou A, Roth B, Rothermundt C, Seiler R, Spahn M, Stenner F,
             Bührer E. Swiss germ-cell cancer consensus recommendations. Swiss
             Med Wkly 2021; 151:.

             Fischer S, Proschmann U, Akgün K, Ziemssen T. Lymphocyte Counts and
             Multiple Sclerosis Therapeutics: Between Mechanisms of Action and
             Treatment-Limiting Side Effects. Cells 2021; 10:.

             Baird R D, Linossi C, Middleton M, Lord S, Harris A, Rodón J, Zitt C,
             Fiedler U, Dawson K M, Leupin N, Stumpp M T, Harstrick A, Azaro A,
             Fischer S, Omlin A. First-in-Human Phase I Study of MP0250, a First-in-
             Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With
             Advanced Solid Tumors. J Clin Oncol 2020; 39:145-154.

             Aeppli S, Eboulet E I, Eisen T, Escudier B, Fischer S, Larkin J, Gruenwald
             V, McDermott D, Oldenburg J, Omlin A, Porta C, Rini B, Schmidinger M,
             Sternberg C, Rothermundt C. Impact of COVID-19 pandemic on
             treatment patterns in metastatic clear cell renal cell carcinoma. ESMO
             Open 2020; 5:.

                                                                            3

Publikationen
             Titel

Wissensch-   Fischer S, Clements S, McWilliam A, Green A, Descamps T, Oing C,
aftlicher    Gillessen S. Influence of abiraterone and enzalutamide on body
Artikel/     composition in patients with metastatic castration resistant prostate
Review       cancer. Cancer Treat Res Commun 2020; 25:100256.

             Fischer S, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B,
             Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J,
             Heidenreich A, Hentrich M, Wheater M, Langberg C W, Ståhl O,
             Fankhauser C D, Hamid A A, Koutsoukos K, Shamash J, White J,
             Bokemeyer C, Beyer J, Gillessen S, Global Germ-Cell Cancer Group .
             Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and
             Cisplatin for Clinical Stage I Nonseminoma. J Clin Oncol 2019;
             JCO1901876.

             Löffler A, Hoffmann S, Fischer S, Spallek J. [Outpatient GP and Specialist
             Care in Rural areas in Germany from the Point of View of Older residents
             in the District of Oberspreewald-Lausitz]. Gesundheitswesen 2019;
             83:47-52.

             Fischer S, Ali O H, Jochum W, Kluckert J T, Flatz L, Siano M. Anti-PD-1
             Therapy Leads to Near-Complete Remission in a Patient with Metastatic
             Basal Cell Carcinoma. Oncol Res Treat 2018; 41:391-394.

             Fischer S, Tandstad T, Wheater M, Porfiri E, Fléchon A, Aparicio J,
             Klingbiel D, Skrbinc B, Basso U, Shamash J, Lorch A, Dieckmann K P,
             Cohn-Cedermark G, Ståhl O, Chau C, Arriola E, Marti K, Hutton P,
             Laguerre B, Maroto P, Beyer J, Gillessen S. Outcome of Men With Relapse
             After Adjuvant Carboplatin for Clinical Stage I Seminoma. J Clin Oncol
             2016; 35:194-200.

             Fischer S, Gillessen S, Rothermundt C. Sequence of treatment in locally
             advanced and metastatic renal cell carcinoma. Transl Androl Urol 2015;
             4:310-25.

                                                                           4

Publikationen
             Titel

Wissensch-   Fischer S, Weber J, Senn-Schönenberger I, Cerny T, Hundsberger T.
aftlicher    Neuroborreliosis Mimicking Leptomeningeal Carcinomatosis in a Patient
Artikel/     With Breast Cancer: A Case Report. J Investig Med High Impact Case Rep
Review       2014; 2:2324709614529417.

                                                                       5

Projekte
Titel                                                          Status

Covid 19 Impfantwort, Bedarf und Reaktion auf mögliche         Laufend
Booster- Impfung bei Patienten mit soliden Neoplasien          -
                                                               Rekrutie-
                                                               rungsph-
                                                               ase

SAKK 67/20 Open-label single-stage phase 1B study of the new Laufend
micellar docetaxel compound Docecal in patients with advanced -
castra-tion-resistant prostate cancer                         Rekrutie-
                                                              rungsph-
                                                              ase

                                                           6

Projekte
Titel                                                           Status

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Laufend
Efficacy of KRT-232 in Combination with Acalabrutinib in       -
Subjects with Relapsed/Refractory Dif-fuse Large B-cell        Rekrutie-
Lymphoma or Relapsed/Refractory Chronic Lymphocytic            rungsph-
Leukemia                                                       ase

MK-7902-005 A Multicenter, Open-label Phase 2 Study of     Geplant
Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in
Previously Treated Subjects with Selected Solid Tumors
(LEAP-005)

A PHASE II, OPEN-LABEL, MULTICENTER STUDY                       Geplant

A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF        Geplant
CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH
UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL
CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO
PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT
INHIBITORS

                                                            7

Projekte
Titel                                                             Status

Rituximab with or without Ibrutinib for untreated patients with   Laufend
advanced follicular lymphoma in need of therapy. A                -
randomized, double-blinded, SAKK and NLG collaborative Phase      Rekrutie-
II trial                                                          rung
                                                                  beendet

An open-label, multicohort, phase II study of MPDL3280A in        Automat-
advanced solid tumors                                             ically
                                                                  closed

Swiss Austrian German Testicular Cancer Cohort Study – SAG        Automat-
TCCS                                                              ically
                                                                  closed

                                                             8